AstraZeneca（AZN）株式概要
バイオ医薬品会社であるアストラゼネカPLCは、医療用医薬品の発見、開発、製造、商業化に注力している。 詳細
AZN Community Fair Values
Create NarrativeSee what 296 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AstraZeneca PLC 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | UK£128.34 |
| 52週高値 | UK£157.32 |
| 52週安値 | UK£101.78 |
| ベータ | 0.22 |
| 1ヶ月の変化 | -4.67% |
| 3ヶ月変化 | -14.37% |
| 1年変化 | 22.81% |
| 3年間の変化 | 24.31% |
| 5年間の変化 | 53.88% |
| IPOからの変化 | 1,832.83% |
最新ニュース
Recent updates
ナラティブの更新 • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.分析記事 • Jun 19
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
ナラティブの更新 • Jun 18
AZN: New Approvals And AI Use Will Support Future Repricing
The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.ナラティブの更新 • Jun 03
AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing
Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.ナラティブの更新 • Apr 29
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.ナラティブの更新 • Apr 15
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.
ナラティブの更新 • Apr 01
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.ナラティブの更新 • Mar 18
AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.ナラティブの更新 • Mar 03
AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.ナラティブの更新 • Feb 17
AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.ナラティブの更新 • Feb 03
AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook
Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.ナラティブの更新 • Jan 20
AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating
Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.ナラティブの更新 • Jan 06
AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns
AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.ナラティブの更新 • Dec 14
AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.ナラティブの更新 • Nov 28
AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects
AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.ナラティブの更新 • Nov 14
AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes
AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.分析記事 • Nov 13
AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest
AstraZeneca PLC's ( LON:AZN ) strong earnings report was rewarded with a positive stock price move. We have done some...ナラティブの更新 • Oct 31
AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance
AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.ナラティブの更新 • Oct 17
Breakthrough Pipeline Therapies And Emerging Markets Will Create Lasting Success
AstraZeneca's analyst price target has been raised from £138.16 to £140.96. This reflects a modest increase as analysts highlight both expanding potential for key pipeline products and a tempered outlook on patent risk and competitive pressures in certain therapeutic areas.株主還元
| AZN | GB Pharmaceuticals | GB 市場 | |
|---|---|---|---|
| 7D | -11.2% | -8.0% | -1.7% |
| 1Y | 22.8% | 22.1% | 16.3% |
業界別リターン: AZN過去 1 年間で22.1 % のリターンをもたらしたUK Pharmaceuticals業界と一致しました。
リターン対市場: AZN過去 1 年間で16.3 % の収益を上げたUK市場を上回りました。
価格変動
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.8% |
安定した株価: AZN 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: AZNの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
バイオ医薬品企業であるアストラゼネカPLCは、医療用医薬品の発見、開発、製造、商業化に注力している。同社は、Imjudo、Datroway、Iressa、Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Crestor、Andexxa、Onglyza、Symlin、XIGDUO XR、Atacand、アタカンドHCT、アタカンドプラス、ファルキシガ／フォルキシガ、プレンディル、モディップ、スプレンディル、ムノバル、フロジル、テノーミン、プレノーミン、アテノール、ゼストリル、ブリリンタ／ブリリーク、コンボグライゼ、Qtern、ワイヌア、バイエッタLokelma、Seloken ZOK、Toprol-XL、Betaloc ZOK、XIGDUO、Accolate、Accoleit、Vanticon、Bricanyl Respules、Eklira Genuair/Tudorza/Bretaris、Pulmicort Turbuhaler、Symbicort Turbuhaler、Airsupra、Bricanylタービュヘーラー、Fasenra、Rhinocort、Tezspire、Bevespi Aerosphere、Daliresp/Daxas、Oxisタービュヘーラー、Saphnelo、Breztri Aerosphere、Duaklir Genuair、Pulmicort Respules、Symbicort pMDI。また、Beyfortus、Kavigale、Evusheld、Fluenz/FluMist、Synagis、Kanuma、Ultomiris、Koselugo、Voydeya、Soliris、Strensiq、Nexiumなどの医薬品も提供している。同社は、がん、循環器、腎臓・代謝、呼吸器・免疫、ワクチン・免疫、希少疾患治療薬などの製品を提供している。英国、アメリカ大陸、その他のヨーロッパ、アジア、アフリカ、オーストラレーシアの販売代理店や現地駐在員事務所を通じて、プライマリーケアおよびスペシャリティケアの医師に製品を提供している。また、Tempus社およびPathos社とは、がん領域で最大規模のマルチモーダルファウンデーションモデルを開発するための戦略的契約を結んでおり、CSPC Pharmaceutical Group Limited社とは、複数の適応症にまたがる疾患の治療が可能な新規経口薬候補の発見と開発を推進するための戦略的契約を結んでいる。前身はゼネカ・グループPLCで、1999年4月にアストラゼネカPLCに社名変更。アストラゼネカPLCは1992年に設立され、英国ケンブリッジに本社を置いている。
AstraZeneca PLC 基礎のまとめ
| AZN 基礎統計学 | |
|---|---|
| 時価総額 | UK£199.06b |
| 収益（TTM） | UK£7.75b |
| 売上高(TTM) | UK£45.11b |
25.7x
PER（株価収益率4.4x
P/SレシオAZN は割高か？
公正価値と評価分析を参照収益と収入
| AZN 損益計算書（TTM） | |
|---|---|
| 収益 | US$60.44b |
| 売上原価 | US$11.18b |
| 売上総利益 | US$49.26b |
| その他の費用 | US$38.87b |
| 収益 | US$10.39b |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 27, 2026
| 一株当たり利益（EPS） | 6.70 |
| グロス・マージン | 81.51% |
| 純利益率 | 17.19% |
| 有利子負債／自己資本比率 | 67.8% |
AZN の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.8%
現在の配当利回り48%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/12 22:23 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AstraZeneca PLC 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。56
| アナリスト | 機関 |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |